Review
Oncogene (2004) 23, 2079–2088. doi:10.1038/sj.onc.1207371
Ubiquitin and breast cancer
Tomohiko Ohta1 and Mamoru Fukuda1
1Division of Breast and Endocrine Surgery, St Marianna University School of Medicine, Kawasaki 216-8511, Japan
Correspondence: T Ohta, E-mail: to@marianna-u.ac.jp
Abstract
The regulation of protein stability by the ubiquitin–proteasome pathway is a critical issue central to the comprehension of the molecular basis of carcinogenesis. However, ubiquitin modification of target substrates signals many cellular processes other than proteolysis that are also important for the development of cancer. It is noteworthy that many proteins studied by clinical breast cancer researchers are involved in these ubiquitin pathways. This review summarizes recent works on such proteins including cyclins, CDK inhibitors, and the SCF in cell cycle control; the breast and ovarian cancer suppressor BRCA1-BARD1; ErbB2/HER2/Neu and its ubiquitin ligase c-Cbl or CHIP; and the estrogen receptor and its downstream target Efp. Understanding these pathways may provide some hints toward developing diagnostic tools and treatments for breast cancer patients.
Keywords:
breast cancer, ubiquitin, RING finger
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Nature Medicine News and Views (01 Jul 2002)
Cdc34: cycling on and off the SCF
Nature Cell Biology News and Views (01 Oct 2003)
RESEARCH
A longevity protein, Lag2, interacts with SCF complex and regulates SCF function
The EMBO Journal Article (04 Nov 2009)
Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth
Nature Letters to Editor (20 Jun 2002)
